Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Feb;113(2 Pt 1):285-92.
doi: 10.1097/AOG.0b013e318193c677.

Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial

Steve N Caritis  1 , Dwight J Rouse, Alan M Peaceman, Anthony Sciscione, Valerija Momirova, Catherine Y Spong, Jay D Iams, Ronald J Wapner, Michael Varner, Marshall Carpenter, Julie Lo, John Thorp, Brian M Mercer, Yoram Sorokin, Margaret Harper, Susan Ramin, Garland Anderson; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Maternal-Fetal Medicine Units Network (MFMU)
Affiliations
Randomized Controlled Trial

Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial

Steve N Caritis et al. Obstet Gynecol. 2009 Feb.

Abstract

Objective: To assess whether 17 alpha-hydroxyprogesterone caproate reduces the rate of preterm birth in women carrying triplets.

Methods: We performed this randomized, double-blinded, placebo-controlled trial in 14 centers. Healthy women with triplets were randomly assigned to weekly intramuscular injections of either 250 mg of 17 alpha-hydroxyprogesterone caproate or matching placebo, starting at 16-20 weeks and ending at delivery or 35 weeks of gestation. The primary study outcome was delivery or fetal loss before 35 weeks.

Results: One hundred thirty-four women were assigned, 71 to 17 alpha-hydroxyprogesterone caproate and 63 to placebo; none were lost to follow-up. Baseline demographic data were similar in the two groups. The proportion of women experiencing the primary outcome (a composite of delivery or fetal loss before 35 0/7 weeks) was similar in the two treatment groups: 83% of pregnancies in the 17 alpha-hydroxyprogesterone caproate group and 84% in the placebo group, relative risk 1.0, 95% confidence interval 0.9-1.1. The lack of benefit of 17 alpha-hydroxyprogesterone caproate was evident regardless of the conception method or whether a gestational age cutoff for delivery was set at 32 or 28 weeks.

Conclusion: Treatment with 17 alpha-hydroxyprogesterone caproate did not reduce the rate of preterm birth in women with triplet gestations.

Clinical trial registration: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00099164

Level of evidence: I.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Randomization, treatment, and follow-up of participants and their offspring.
Figure 2
Figure 2
The proportion of randomized subjects who remained undelivered and with three living fetuses according to the gestational age and treatment group.
See this image and copyright information in PMC

References

    1. Alexander GR, Salihu HM. Perinatal outcomes of singleton and multiple births in the United States, 1995-98. In: Blickstein I, Keith G, editors. Multiple Pregnancy. Taylor and Francis; London and New York: 2005. pp. 3–10.
    1. Mathews TJ, MacDorman MF. National vital statistics reports. 16. Vol. 54. Hyattsville, MD: National Center for Health Statistics; 2006. Infant mortality statistics from the 2003 period linked birth/infant death data set. - PubMed
    1. Meis PJ, Klebanoff M, Thom E, et al. Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate. N Engl J Med. 2003;348:2379–85. - PubMed
    1. Rouse DJ, Caritis SN, Peaceman AM, et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med. 2007;357:454–61. - PubMed
    1. Carey JC, Klebanoff MA, Hauth JC, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. N Engl J Med. 2000;342:534–540. - PubMed

Publication types

Associated data

Grants and funding